Stephen V. Liu, MD, Georgetown University

Articles by Stephen V. Liu, MD, Georgetown University

Future of Optimal Maintenance Therapy in ES-SCLC

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 27th 2026

Experts explore biomarkers, sequencing, and access strategies for extensive-stage small cell lung cancer maintenance, spotlighting tarlatamab, ADC combos, and clinical trials.

Dosing Strategies and Real World Implementation of Maintenance Therapy

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 20th 2026

Relapsed small cell lung cancer care evolves as tarlatamab boosts survival but needs CRS/ICANS monitoring, while lurbinectedin offers simpler dosing.

Applying IMforte Data to a Clinical Scenario

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 20th 2026

Experts weigh maintenance options after chemo-immunotherapy in extensive-stage SCLC, navigating brain mets, cytopenias, and real-world care barriers.

Management of Brain Metastases in Extensive Stage Small Cell Lung Cancer

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 13th 2026

Experts weigh brain metastases limits in IMFORTA and share real-world tips for maintenance lurbinectedin plus atezolizumab.

Safety Profile of Lurbinectedin and Patient Selection for Maintenance Therapy

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 13th 2026

Experts weigh IMfortis data, side effects, and patient selection as lurbinectedin-atezolizumab maintenance reshapes extensive-stage SCLC care.

Reviewing the IMforte Phase 3 Data in Extensive Stage Small Cell Lung Cancer

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 6th 2026

IMforté data show larotrectinib plus atezolizumab maintenance extends PFS and OS in extensive-stage small cell lung cancer—real-world considerations.

First Line Maintenance in Extensive Stage Small Cell Lung Cancer

ByStephen V. Liu, MD, Georgetown University,Ticiana A. Leal, MD

March 6th 2026

Experts unpack IMfortis data on intensifying atezolizumab maintenance after induction chemoimmunotherapy in extensive-stage small cell lung cancer.

Dr Liu on the Activity of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

ByStephen V. Liu, MD, Georgetown University

April 14th 2023

Stephen V. Liu, MD, discusses the activity of trastuzumab deruxtecan in patients with HER2-mutated non–small cell lung cancer.

Rapid Readouts: Safety and Efficacy of Pralsetinib in Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer: Update from the ARROW trial

ByStephen V. Liu, MD, Georgetown University

July 13th 2021

Stephen V. Liu, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the ARROW trial of pralsetinib in patients with RET fusion-positive non-small cell lung cancer.

Emerging Agents and Future of Small Cell Lung Cancer

ByJared Weiss, MD, University of North Carolina at Chapel Hill ,Stephen V. Liu, MD, Georgetown University

April 2nd 2021

Jared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.

Management of ES-SCLC: Second Line and Beyond

ByJared Weiss, MD, University of North Carolina at Chapel Hill ,Stephen V. Liu, MD, Georgetown University

April 2nd 2021

Considerations for second-line treatment regimens, the role of immunotherapy in the relapsed/refractory setting, and using lurbinectedin for the management of ES-SCLC.

Using Trilaciclib for Treatment of ES-SCLC

ByJared Weiss, MD, University of North Carolina at Chapel Hill ,Stephen V. Liu, MD, Georgetown University

April 2nd 2021

Stephen V. Liu, MD, and Jared Weiss, MD, share their thoughts on the impact of the recent approval of trilaciclib prior to platinum/etoposide-based chemotherapy for the treatment of ES-SCLC.

Standard of Care for ES-SCLC

ByJared Weiss, MD, University of North Carolina at Chapel Hill ,Stephen V. Liu, MD, Georgetown University

March 25th 2021

Experts in thoracic oncology review data from the IMpower133 and CASPIAN trials as well as the use of chemotherapy with PD-L1 inhibitors for treatment-naïve ES-SCLC in clinical practice.

Staging for Small-Cell Lung Cancer

ByJared Weiss, MD, University of North Carolina at Chapel Hill ,Stephen V. Liu, MD, Georgetown University

March 25th 2021

Insights on the differences between limited-stage and extensive-stage small-cell lung cancer and recent progress made with combination chemotherapy plus immunotherapy.